Literature DB >> 23774168

Aberrant expression of p63 in adenocarcinoma of the prostate: a radical prostatectomy study.

Giovanna A Giannico1, Hillary M Ross, Tamara Lotan, Jonathan I Epstein.   

Abstract

Prostatic adenocarcinoma with aberrant diffuse expression of p63 (p63-PCa) is a recently described variant of prostatic adenocarcinoma. The aim of this study was to investigate the clinical and pathologic features of p63-PCa at radical prostatectomy (RP). We reviewed 21 cases of p63-PCa diagnosed on needle biopsy at subsequent RP. Immunohistochemical analysis for PIN4 and Ki-67 was performed in all RP cases. p63-PCa showed a distinctive morphology consisting of atrophic, poorly formed glands, with multilayered and often spindled nuclei. Gleason grading was 3+3=6 in 28.5%, 3+5=8 in 38%, 3+4=7 in 14.3%, and 4+3=7, 5+3=8, and 5+4=9 in 9.5%. Usual-type acinar carcinoma coexisted in 85.7% with only p63-PCa present in the remaining cases. The usual-type carcinoma was Gleason grade 3+2=5 in 4.7%, 3+3=6 in 57%, 3+4=7 in 19%, and 4+3=7 in 4.3%. Overall, p63-PCa represented 65% of the total cancer volume (median 80%). The tumor was organ-confined in 16 cases (76.2%). In the remaining 5 cases, 2 had p63-PCa extending to the margin in areas of intraprostatic incisions, 2 had usual-type acinar adenocarcinoma extending to the margin and extraprostatic tissue, respectively, and 1 had p63-PCa with an unusual cribriform morphology involving the bladder neck. Ki-67 was low, <5% in all cases of p63-PCa, with similar expression in the coexisting acinar-type carcinoma. In summary, it is recommended that these tumors not be assigned a Gleason score and their favorable findings at RP be noted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23774168     DOI: 10.1097/PAS.0b013e31828d5c32

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

Review 1.  The pathology of unusual subtypes of prostate cancer.

Authors:  Jing Li; Zhe Wang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

2.  Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors.

Authors:  Supreet Agarwal; Paul G Hynes; Heather S Tillman; Ross Lake; Wassim G Abou-Kheir; Lei Fang; Orla M Casey; Amir H Ameri; Philip L Martin; Juan Juan Yin; Phillip J Iaquinta; Wouter R Karthaus; Hans C Clevers; Charles L Sawyers; Kathleen Kelly
Journal:  Cell Rep       Date:  2015-11-25       Impact factor: 9.423

Review 3.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

4.  ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.

Authors:  Alba Torres; Mohammed Alshalalfa; Elai Davicioni; Anuj Gupta; Srinivasan Yegnasubramanian; Sarah J Wheelan; Jonathan I Epstein; Angelo M De Marzo; Tamara L Lotan
Journal:  Prostate       Date:  2018-05-15       Impact factor: 4.104

5.  GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States.

Authors:  Igor Vidal; Qizhi Zheng; Jessica L Hicks; Jiayu Chen; Elizabeth A Platz; Bruce J Trock; Ibrahim Kulac; Javier A Baena-Del Valle; Karen S Sfanos; Sarah Ernst; Tracy Jones; Janielle P Maynard; Stephanie A Glavaris; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  PLoS One       Date:  2021-06-30       Impact factor: 3.240

6.  Prostate adenocarcinoma of secretory type with wide expression of p63 and negativity of the basal marker Ck5/6: Rare subtype of adenocarcinoma of secretory origin and to be differentiated from basal cell carcinoma. Review of literature.

Authors:  Abbas M; Habibian B; Bettendorf O
Journal:  Rare Tumors       Date:  2020-12-01

7.  Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas.

Authors:  Hsueh-Li Tan; Michael C Haffner; David M Esopi; Ajay M Vaghasia; Giovanna A Giannico; Hillary M Ross; Susmita Ghosh; Jessica L Hicks; Qizhi Zheng; Ankur R Sangoi; Srinivasan Yegnasubramanian; Adeboye O Osunkoya; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

8.  Single luminal epithelial progenitors can generate prostate organoids in culture.

Authors:  Chee Wai Chua; Maho Shibata; Ming Lei; Roxanne Toivanen; LaMont J Barlow; Sarah K Bergren; Ketan K Badani; James M McKiernan; Mitchell C Benson; Hanina Hibshoosh; Michael M Shen
Journal:  Nat Cell Biol       Date:  2014-09-21       Impact factor: 28.824

9.  Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression.

Authors:  Carlos Eduardo Fonseca-Alves; Priscila Emiko Kobayashi; Luis Gabriel Rivera Calderón; Sérgio Luis Felisbino; Jaqueline de Carvalho Rinaldi; Sandra Aparecida Drigo; Silvia Regina Rogatto; Renée Laufer-Amorim
Journal:  PLoS One       Date:  2018-06-12       Impact factor: 3.240

Review 10.  Primary mucinous adenocarcinoma of the eyelid: A case report and literature review.

Authors:  Abdulkader M Albasri; Irfan A Ansari; Abdulaziz R Aljohani; Ahmed S Alhujaily
Journal:  Saudi Med J       Date:  2018-09       Impact factor: 1.484

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.